Skip to main content

Table 2 Non-recurrent vs. recurrent group

From: Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy

 All patientsNon-recurrentRecurrentp value
Age (n)32239 
 Median, IQR83, 79–8583, 79–8582, 81–850.916
Gender
 Female13941.000
 Male19145 
Histology
 Ad241860.655
 Non-Ad853 
Morphology
 Solid/part solid261790.150
 GGO660 
Dose
 40 Gy (PTV D95)231760.685
 48 Gy (isocenter)963 
Tumor diameter23.0, 17.0–32.321.0, 15.0–27.528.0, 26.0–35.00.013
FDG SUVmax7.89, 2.00–10.16.02, 1.81–8.949.73, 8.46–13.20.005
FDG MTV6.62, 1.15–10.06.21, 3.71–9.508.19, 3.52–10.80.586
FMISO SUVmax1.50, 0.88–2.051.15, 0.82–1.592.21, 1.90–2.74< 0.001
FMISO TMR1.11, 0.72–1.800.83, 0.68–1.192.22, 1.79–2.44< 0.001
FMISO TBR0.91, 0.63–1.410.75, 0.60–1.041.70, 1.37–1.80< 0.001
  1. FDG fluorodeoxyglucose, FMISO fluoromisonidazole, IQR interquartile range, MTV metabolic tumor volume, PTV planning target volume, SUVmax maximum of standardized uptake value, TBR tumor-to-blood ratio, TMR tumor-to-muscle ratio